FDA's decision not to approve AstraZeneca PLC's fixed-dose product combining two oral antidiabetic agents comes with a somewhat surprising request – more clinical data.
Both elements of the product – which combines the DPP-4 inhibitor Onglyza (saxagliptin) and the SGLT2 inhibitor Farxiga (dapagliflozin) for...